Home LiteratureArticle Details
PMID: 9234682 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Efficient repression of endogenous major histocompatibility complex class II expression through dominant negative CIITA mutants isolated by a functional selection strategy.

Molecular and cellular biology ·Vol. 17 ·No. 8 ·1997-08-00 ·Pages 4249-58

Bontron S, Ucla C, Mach B, Steimle V

Abstract

Major histocompatibility complex class II (MHC-II) molecules present peptide antigens to CD4-positive T cells and are of critical importance for the immune response. The MHC-II transactivator CIITA is essential for all aspects of MHC-II gene expression examined so far and thus constitutes a master regulator of MHC-II expression. In this study, we generated and analyzed mutant CIITA molecules which are able to suppress endogenous MHC-II expression in a dominant negative manner for both constitutive and inducible MHC-II expression. Dominant negative CIITA mutants were generated via specific restriction sites and by functional selection from a library of random N-terminal CIITA deletions. This functional selection strategy was very effective, leading to strong dominant negative CIITA mutants in which the N-terminal acidic and proline/serine/threonine-rich regions were completely deleted. Dominant negative activity is dependent on an intact C terminus. Efficient repression of endogenous MHC-II mRNA levels was quantified by RNase protection analysis. The quantitative effects of various dominant negative CIITA mutants on mRNA expression levels of the different MHC-II isotypes are very similar. The optimized dominant negative CIITA mutants isolated by functional selection should be useful for in vivo repression of MHC-II expression.

MeSH Terms
Burkitt Lymphoma Cell Separation Cloning, Molecular DNA, Recombinant Flow Cytometry Genes, Dominant Genes, MHC Class II/genetics HLA-DR Antigens/genetics HeLa Cells Humans Interferon-gamma/pharmacology Nuclear Proteins RNA, Messenger/biosynthesis Sequence Deletion Trans-Activators/analysis,genetics,metabolism Transcriptional Activation/genetics Tumor Cells, Cultured
Chemicals
DNA, Recombinant HLA-DR Antigens MHC class II transactivator protein Nuclear Proteins RNA, Messenger Trans-Activators Interferon-gamma
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Bontron S
Department of Genetics and Microbiology, University of Geneva Medical School, Switzerland.
Ucla C
Mach B
Steimle V
References (43)
43 references, click to expand
  1. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis.
    Cell. 1978 May;14(1):9-20 PMID: 667938
  2. Two novel mutations in the MHC class II transactivator CIITA in a second patient from MHC class II deficiency complementation group A.
    Hum Genet. 1997 Apr;99(4):541-6 PMID: 9099848
  3. Detection of a novel human class II HLA antigen.
    Nature. 1983 Jul 28-Aug 3;304(5924):358-61 PMID: 6192342
  4. A bacteriophage T7 RNA polymerase/promoter system for controlled exclusive expression of specific genes.
    Proc Natl Acad Sci U S A. 1985 Feb;82(4):1074-8 PMID: 3156376
  5. A eukaryotic transcriptional activator bearing the DNA specificity of a prokaryotic repressor.
    Cell. 1985 Dec;43(3 Pt 2):729-36 PMID: 3907859
  6. Analysis by sequential immunoprecipitations of the specificities of the monoclonal antibodies TU22,34,35,36,37,39,43,58 and YD1/63.HLK directed against human HLA class II antigens.
    Immunobiology. 1986 Mar;171(1-2):77-92 PMID: 3486813
  7. Differential presentation of HLA-DR, DQ, and DP restriction elements by interferon-gamma-treated dermal fibroblasts.
    J Immunol. 1987 Aug 1;139(3):715-23 PMID: 3110281
  8. Functional inactivation of genes by dominant negative mutations.
    Nature. 1987 Sep 17-23;329(6136):219-22 PMID: 2442619
  9. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat.
    Mol Cell Biol. 1988 Jan;8(1):466-72 PMID: 2827008
  10. Congenital immunodeficiency with a regulatory defect in MHC class II gene expression lacks a specific HLA-DR promoter binding protein, RF-X.
    Cell. 1988 Jun 17;53(6):897-906 PMID: 3133120
  11. RNA isolation: a mini-prep method.
    Nucleic Acids Res. 1988 Nov 25;16(22):10933 PMID: 2462717
  12. Inherited immunodeficiency with a defect in a major histocompatibility complex class II promoter-binding protein differs in the chromatin structure of the HLA-DRA gene.
    Mol Cell Biol. 1989 Jan;9(1):296-302 PMID: 2467188
  13. Differential surface expression of class II isotypes on activated CD4 and CD8 cells correlates with levels of locus-specific mRNA.
    J Immunol. 1989 May 1;142(9):3275-80 PMID: 2785139
  14. Regulation of major histocompatibility complex class-II genes: X, Y and other letters of the alphabet.
    Annu Rev Immunol. 1990;8:681-715 PMID: 2111709
  15. Gamma-interferon induces differential expression of HLA-DR, -DP and -DQ in human ciliary epithelial cells.
    Graefes Arch Clin Exp Ophthalmol. 1991;229(2):191-4 PMID: 1904385
  16. Transformation suppressor activity of a Jun transcription factor lacking its activation domain.
    Nature. 1991 Aug 15;352(6336):635-8 PMID: 1907719
  17. Structural studies of the acidic transactivation domain of the Vmw65 protein of herpes simplex virus using 1H NMR.
    Biochemistry. 1992 Apr 28;31(16):4150-6 PMID: 1314658
  18. Sequences and factors: a guide to MHC class-II transcription.
    Annu Rev Immunol. 1992;10:13-49 PMID: 1590984
  19. Different activation domains stimulate transcription from remote ('enhancer') and proximal ('promoter') positions.
    EMBO J. 1992 Dec;11(13):4961-8 PMID: 1464321
  20. Following a diabetogenic T cell from genesis through pathogenesis.
    Cell. 1993 Sep 24;74(6):1089-100 PMID: 8402882
  21. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome).
    Cell. 1993 Oct 8;75(1):135-46 PMID: 8402893
  22. Ectopic expression of wild-type or a dominant-negative mutant of transcription factor NTF-1 disrupts normal Drosophila development.
    Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10563-7 PMID: 8248145
  23. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA.
    Science. 1994 Jul 1;265(5168):106-9 PMID: 8016643
  24. p53 domains: structure, oligomerization, and transformation.
    Mol Cell Biol. 1994 Aug;14(8):5182-91 PMID: 8035799
  25. Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA.
    J Exp Med. 1994 Oct 1;180(4):1329-36 PMID: 7931066
  26. Evidence for a specific post-transcriptional mechanism controlling the expression of HLA-DQ, but not -DR and -DP, molecules.
    J Immunol. 1994 Nov 15;153(10):4530-8 PMID: 7525708
  27. Mutant p53 proteins behave in a dominant, negative fashion in vivo.
    Anticancer Res. 1994 Sep-Oct;14(5A):1853-9 PMID: 7847818
  28. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome).
    Genes Dev. 1995 May 1;9(9):1021-32 PMID: 7744245
  29. Activation of class II MHC genes requires both the X box region and the class II transactivator (CIITA).
    Immunity. 1995 May;2(5):533-43 PMID: 7749984
  30. Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency.
    Immunity. 1995 May;2(5):545-53 PMID: 7749985
  31. Genomic stability and wild-type p53 function of lymphoblastoid cells with germ-line p53 mutation.
    Oncogene. 1995 Jun 15;10(12):2447-54 PMID: 7784096
  32. A role for the orphan steroid receptor Nur77 in apoptosis accompanying antigen-induced negative selection.
    Immunity. 1995 Sep;3(3):273-82 PMID: 7552993
  33. Human anti-porcine xenogeneic T cell response. Evidence for allelic specificity of mixed leukocyte reaction and for both direct and indirect pathways of recognition.
    J Immunol. 1995 Dec 1;155(11):5249-56 PMID: 7594537
  34. Proteins with leucine-rich repeats.
    Curr Opin Struct Biol. 1995 Jun;5(3):409-16 PMID: 7583641
  35. Molecular defects in the bare lymphocyte syndrome and regulation of MHC class II genes.
    Immunol Today. 1995 Nov;16(11):539-46 PMID: 7495492
  36. Characterization of the expressed CIITA allele in the class II MHC transcriptional mutant RJ2.2.5.
    Immunogenetics. 1996;43(1-2):88-91 PMID: 8537130
  37. Tissue-specific inactivation of p53 tumor suppression in the mouse.
    Genes Dev. 1996 Apr 1;10(7):826-35 PMID: 8846919
  38. Checkpoints in the progression of autoimmune disease: lessons from diabetes models.
    Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2260-3 PMID: 8637860
  39. Regulation of MHC class II genes: lessons from a disease.
    Annu Rev Immunol. 1996;14:301-31 PMID: 8717517
  40. The use of dominant-negative mutations to elucidate signal transduction pathways in lymphocytes.
    Curr Opin Immunol. 1996 Apr;8(2):285-90 PMID: 8725953
  41. Xenotransplantation: recent progress and current perspectives.
    Curr Opin Immunol. 1996 Oct;8(5):721-8 PMID: 8902399
  42. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency.
    EMBO J. 1997 Mar 3;16(5):1045-55 PMID: 9118943
  43. Analysis of HLA-D region-associated molecules with monoclonal antibody.
    Proc Natl Acad Sci U S A. 1979 Dec;76(12):6567-71 PMID: 392522
Article Info
Journal
Molecular and cellular biology
Abbr.
Mol Cell Biol
ISSN
0270-7306
Published
1997-08-00
Pages
4249-58
Language
English
Region
United States
NLM ID
8109087
PMCID
PMC232278
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com